---
title: "Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy"
description: "This is a randomized, multi-center, single dose, open-label and Neulasta controlled phase 3 study to evaluate the efficacy and safety of F-627 in women wit"
url: "https://www.clareohealth.com/clinical-trials/NCT03252431"
---

This is a randomized, multi-center, single dose, open-label and Neulasta controlled phase 3 study to evaluate the efficacy and safety of F-627 in women with Stage I - III invasive breast cancer receiving chemotherapy treatment.

## Key Facts

**ID:** NCT03252431
**Status:** COMPLETED
**Phase:** PHASE3
**Type:** INTERVENTIONAL
**Enrollment:** 393
**Sponsor:** EVIVE Biotechnology

## About This Study

This clinical trial is testing F-627, a new treatment, against Neulasta, a standard medication, in women with Stage I-III breast cancer who are receiving chemotherapy. The goal is to see which treatment better helps manage a side effect called severe neutropenia, which is a dangerously low white blood cell count.

## Detailed Description

This is a Phase III, global, two arm, open label clinical study will randomize approximately 400 female subjects (approximately 200 per arm) with Stage I - III invasive breast cancer who are to receive neoadjuvant or adjuvant myelotoxic TC chemotherapy treatment (docetaxel + cyclophosphamide, 75 and 600 mg/m2, respectively). Subjects in this study will be those who are scheduled to undergo at least four 21-day cycles of chemotherapy treatment. Subjects may be scheduled for more than 4 cycles of chemotherapy; however, study participation will be limited to a subject's first 4 cycles. The primary objective of this study will be to evaluate the efficacy of F-627 given as a single fixed dose (20 mg) pre-filled syringe as compared to Neulasta® standard dosing (6 mg) in the first chemotherapy cycle. The primary endpoint will be the duration of grade 4 (severe) neutropenia - the number of days in which the patient has had an absolute neutrophil count (ANC \<0.5 x 10\^9/L) observed in chemotherapy cycle 1. Approximately 24 hours after chemotherapy completion in each cycle (Day 2 of the cycle), subjects will receive one of the following treatments: Arm 1: F-627, 20 mg fixed dose pre-filled syringe, administered on Day 2 of each of 4 chemotherapy cycles. Arm 2: 6 mg fixed dose Neulasta®, administered on Day 2 of each of 4 chemotherapy cycles Randomization will occur in an equal ratio (1:1) using a central randomization system (IWRS) on Day 1 of the study, the day of chemotherapy administration for the first chemotherapy cycle. This study is open-label, however, study drug injections are to be administered separately by qualified study personnel to allow study investigators to remain blinded and perform study assessments without knowledge of treatment assignment.

## Conditions

- Breast Cancer
- Neutropenia

## Interventions

**DRUG: F-627**
single dose pre-filled syringe

**DRUG: Neulasta**
single dose pre-filled syringe

## Eligibility

Inclusion Criteria: 1.

## Who Can Participate

**Minimum age:** 18

**Sex:** FEMALE

**Accepts healthy volunteers:** No

## Study Locations

- University of California Los Angeles (UCLA) - Jonsson Comprehensive Cancer Center (JCCC), Los Angeles, California, United States

## Contact Information

## Important Dates

**Study start:** April 12, 2018

**Completion date:** March 5, 2020

**Last updated:** July 3, 2023

## Consider Discussing with Your Care Team

### Worth Discussing If

- You have Stage I-III breast cancer and are scheduled for chemotherapy.
- You are concerned about the risk of severe neutropenia during your treatment.
- You are interested in exploring new treatment options that might improve your care.

### Questions to Ask

- What are the potential benefits of participating in this trial compared to my current treatment?
- How will the side effects of F-627 compare to Neulasta?
- What kind of monitoring will I need during the trial?
- How will my participation affect my overall treatment plan?
- Are there any risks I should be aware of with this new treatment?
- What happens if I experience severe side effects?

[View on ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03252431)
